Mutations in KRAS [18,24] and TP53 [15,24] were reported with shorter outcome survival and increased tumor recurrence rate, associated with higher levels of protein biomarkers EGFR, MUC1, MUC4, and fascin expression and lower levels of p27 expression, in addition to higher expression of miRNA21 [15]. Here, TP53 is linked to neoplasm.